Abstracts tagged "pulmonary"

Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos², Jasneet Singh², Ingrid Lazaridou², Markos Kalligeros², Eleftherios Mylonakis³ and Anthony M. Reginato⁴, ¹Warren Alpert Medical School of Brown University, Providence, RI, ²Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, RI, ³Department of Medicine, Houston Methodist Hospital, Houston, ⁴Brown University, Providence, RI
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…
Abstract Number: 1528 • ACR Convergence 2024
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
Maria Romero Noboa¹, Almurtada Razok², Husam El Sharu³ and Rafaella Litvin², ¹University of Alabama at Birmingham, Chicago, IL, ²John H Stroger Jr Hospital of Cook County, Chicago, IL, ³East Carolina University, Greenville, NC
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a range of pulmonary complications, including Pulmonary Arterial Hypertension (PAH), which affects between 0.5% and 17.5% of…
Abstract Number: 2492 • ACR Convergence 2024
ANCA Associated Tracheobronchial Disease
Megan Sullivan¹, Maximiliano Diaz Menindez², Ronald Butendieck³, hassan baig⁴, Anushka Irani⁵, Benjamin Wang³, Florentina Berianu⁵, Carolyn Mead-Harvey⁶, Andy Abril⁵ and Vikas Majithia⁴, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic, Ponte Vedra Beach, FL, ⁶Mayo Clinic, Scottsdale, AZ
Background/Purpose: Tracheobronchial disease is a common manifestation of ANCA associated vasculitis (AAV). However, outcomes data is commonly unreported in prospective studies. We performed a retrospective…
Abstract Number: 0678 • ACR Convergence 2024
Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Oliver Distler¹, Margarida Alves², Gerrit Toenges³ and Anna-Maria Hoffmann-Vold⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
Abstract Number: 1559 • ACR Convergence 2024
Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
S. Ahmed¹, Eva Hoekstra², Katie van der Wouden², Sum-Che Man², Kees Swenne², Madelon Vonk³, Anna-Maria Hoffmann-Vold⁴, Cosimo Bruni⁵, Udo Mulder⁶, Thomas Huizinga⁷, H.W. Vliegen² and Jeska de Vries-Bouwstra², ¹Leiden University Medical Centre, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Oslo University Hospital, Oslo, Norway, ⁵University of Zurich, Zurich, Switzerland, ⁶Universitair Medisch Centrum Groningen, Groningen, Netherlands, ⁷Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Pulmonary hypertension (PH) in SSc causes significant disease burden and requires invasive diagnosis with right heart catheterization (RHC). Comprehensive work-up is needed to identify…
Abstract Number: 2495 • ACR Convergence 2024
Diffuse Alveolar Hemorrhage in Patient with ANCA-associated Vasculitis AndInterstitial Lung Disease
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba² and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: The association of interstitial lung disease (ILD) and microscopic polyangiitis (MPA) is increasingly recognized. The implications of ILD as it relates to clinical outcomes…
Abstract Number: 0693 • ACR Convergence 2024
Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors
Miriam Retuerto Guerrero¹, Clara Moriano², Paula Perez Garcia³, cristiana sieiro santos⁴ and elvira Diez álvarez³, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain
Background/Purpose: Bronchiectasis (BC) has been observed in association with Systemic Sclerosis (SSc). Esophageal dysmotility, immunosuppressive drugs and the direct effect of collagen deposition in the…
Abstract Number: 1561 • ACR Convergence 2024
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…
Abstract Number: 2522 • ACR Convergence 2024
Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event
Kerem Abacar¹, Ayşe Elif Boncukcuoğlu¹, Aysun Aksoy², Derya Kocakaya¹, Çagatay Cimşit¹, Haner Direskeneli³ and Fatma Alibaz Öner³, ¹Marmara University, istanbul, Turkey, ²Alaaddin Keykubat University, Antalya, Turkey, ³Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome.…
Abstract Number: 0714 • ACR Convergence 2024
Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba², Robert McBane¹ and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an acutely life-threating presentation of ANCA-associated vasculitis (AAV), and patients with AAV are at increased risk of venous thromboembolic…
Abstract Number: 1595 • ACR Convergence 2024
Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Margot Poux¹, Matthieu Groh², Alexandra Nanzerkelly³, Marco Caminati⁴, candice Lacroix⁵, stephanie Habib⁶ and Benjamin Terrier⁷, ¹Université de Paris cité, PARIS 04EME, France, ²Foch, Suresnes, France, ³King's college London, London, ⁴Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ⁵Université de Paris cité, Paris, ⁶Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis associated with asthma and blood and tissue eosinophilia. EGPA is often associated with glucocorticoid…
Abstract Number: 2570 • ACR Convergence 2024
Comparison of the Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis- Associated Lung Disease (SJIA-LD) Cohort to CARRA Registry SJIA Patients Without Lung Disease
Esraa Eloseily¹, Autumn Clark¹, Min-Lee Chang², Mary Ellen Riordan³, Alan Russell⁴, Marc Natter⁵, Scott Canna⁶, Sherry Thornton⁷, Yukiko Kimura⁸ and grant schulert¹, and CARRA FROST Investigators and the CARRA Registry SJIA-LD Cohort Investigators, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, ³Hackensack University Medical Center, Westwood, NJ, ⁴Duke Clinical Research Institute, Durham, NC, ⁵Boston Children's Hospital, Boston, MA, ⁶Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Cincinnati Children's Hospital, Cincinnati, ⁸Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging life-threatening disease with urgent unmet knowledge gaps. This study compares the clinical…
Abstract Number: 0715 • ACR Convergence 2024
Diffuse Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Revisited
Samuel Falde¹, Elif Ediboglu¹, Misbah Baqir¹, Rodrigo Cartin-Ceba², Fernando C. Fervenza¹, Ladan Zand¹, Matthew Koster¹, Kenneth Warrington¹ and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: We sought to characterize the most recent cohort of patients presenting with DAH and AAV and to identify risk factors for respiratory failure and…
Abstract Number: 1693 • ACR Convergence 2024
Change in Forced Vital Capacity at Week 12 or 24 Has Prognostic Value for Outcome at Week 52 in Patients with Autoimmune Disease-Related Interstitial Lung Diseases
Anna-Maria Hoffmann-Vold¹, Margarida Alves², Corinna Miede³ and Oliver Distler⁴, ¹Oslo University Hospital, Oslo, Norway, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Clinical trials in patients with interstitial lung diseases (ILDs) generally include a 52-week treatment period. Shorter trials would help speed up drug development and…
Abstract Number: 2645 • ACR Convergence 2024
Human NCF1-p.R90H Variant Promotes Pulmonary Fibrosis in the Bleomycin-induced Mouse Model and Systemic Sclerosis Patients via Expansion of SPP1+Monocytes-derived Macrophages
Xinran Yuan¹, Xiaodong Qin², Kenji Takemoto¹, Jian Zhao¹, Matthew Sanderson¹, Xue Xu¹, Kristi L Helke³, Bethany Wolf⁴, Joel Guthridge⁵, Judith A James⁶, Xiaodong Zhou⁷, Shervin Assassi⁸, Carol Feghali-Bostwick⁴, Dandan Wang⁹, Lingyun Sun¹⁰ and Betty P Tsao¹, ¹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China (People's Republic), ³Department of Comparative Medicine, Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Division of Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁸UTHealth Houston Division of Rheumatology, Houston, TX, ⁹Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical Schoo, Nanjing, Jiangsu, China (People's Republic), ¹⁰Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China (People's Republic)
Background/Purpose: We previously identified a systemic lupus erythematosus (SLE) causal risk variant, p.Arg90His (p.R90H, rs201802880) substitution encoded in neutrophil cytosolic factor 1 (NCF1), an essential component…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].